Galvin Roy (CIK 1950021) reported 7 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-05-19). Recent activity: Sell HAE (879 shares), Buy HAE (27,535 shares), Sell HAE (145 shares), Buy HAE (5,689 shares), Buy HAE (6,755 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-19 | HAEMONETICS CORP (HAE) | EVP, Chief Commercial Officer | Sell | 879 | $49,479 |
| 2026-05-19 | HAEMONETICS CORP (HAE) | EVP, Chief Commercial Officer | Buy | 27,535 | $0 |
| 2025-11-03 | HAEMONETICS CORP (HAE) | EVP, Chief Commercial Officer | Sell | 145 | $7,251 |
| 2025-06-13 | HAEMONETICS CORP (HAE) | EVP, Chief Commercial Officer | Buy | 5,689 | $0 |
| 2025-05-20 | HAEMONETICS CORP (HAE) | President, Global Plasma & BC | Buy | 6,755 | $0 |
| 2025-05-19 | HAEMONETICS CORP (HAE) | President, Global Plasma & BC | Sell | 201 | $13,945 |
| 2025-05-19 | HAEMONETICS CORP (HAE) | President, Global Plasma & BC | Sell | 257 | $18,070 |
Source: SEC Form 4 filings · as of 2026-05-19